Novartis announces major United States deal

The Novartis pharmaceutical group says it will buy the Genoptix specialised cancer laboratory in the American state of California for $470 million (SFr452 million).

This content was published on January 24, 2011 - 11:22 and agencies

A statement from Basel-based Novartis on Monday said the acquisition would strengthen its diagnostics operations and diversify its operations further.

The Genoptix board is recommending shareholders accept an offer of $25 per share, which represents a premium of 27 per cent over Friday’s closing price.

Novartis said Genoptix, which specialises in diagnosing cancers in bone marrow, blood and lymph nodes, had sales of $184 million in 2009, employed a staff of 500 and was profitable.

The Swiss group last year bought the Texas-based Alcon eye care company for about $52 billion, including the shares held by the Nestlé food company.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.